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Despite tremendous development in chemotherapy for ovarian cancer over the past few decades, the prognosis of advanced cases
with massive peritoneal dissemination is still unsatisfactory, and novel treatment modalities that can combine with chemotherapy
are urgently needed. We recently developed virotherapy for solid tumors using telomerase-specific replication-selective
adenoviruses (Telomelysin: OBP-301), in which the human telomerase reverse transcriptase (hTERT) gene promoter has been
inserted to direct tumor-specific E1 gene expression. In this study, we investigated the anti-tumor effects of OBP-301, combined
with cisplatin (CDDP), on ovarian cancer cells. In vitro treatment of SKOV3 cells with OBP-301 at a multiplicity of infection (MOI)
of 0.01–100 induced significant cell death in a dose-dependent manner, with moderate cytotoxicity at an MOI of 1–10 and
maximal cytotoxicity at an MOI of 100. In contrast, OBP-301 treatment of normal human cells showed no significant cell death at
an MOI of 1–10 and exhibited modest cytotoxicity at an MOI of 100. The effects of low-dose CDDP at 0.5–1mM, which induced
only 20% cell death, were significantly augmented by combination with OBP-301 at an MOI of 1–10, finally achieving 40% cell
death. Such enhancement of CDDP sensitivity was also observed in CDDP-resistant ovarian cancer cells. The combinatorial effects
were further tested using a xenograft mouse model of SKOV3 with peritoneal dissemination. After intraperitoneal administration of
OBP-301, we confirmed that injected OBP-301 fused with the green fluorescent protein (GFP) gene (OBP-401) was preferentially
localized to peritoneal disseminations, as determined by fluorescence imaging. Treatment of mice with CDDP at low dose
(0.5mgkg
–1) had modest effects, showing a 10% decrease in disseminations, whereas combination with intraperitoneal
administration of OBP-301 at an MOI of 10 led to enhanced effects, achieving an approximately 80% decrease in disseminations.
Kaplan–Meier analysis showed improved overall survival of mice treated with CDDP plus OBP-301 compared with CDDP alone.
These findings support the therapeutic potential of intraperitoneal administration of OBP-301 to sensitize ovarian cancer cells to
CDDP.
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Introduction
Surgical tumor reduction and subsequent platinum-based
chemotherapy has been considered as the standard
therapy for advanced ovarian cancer over the past few
decades.
1 Despite advances in the development of
chemotherapeutic agents, the prognosis of advanced
ovarian cancer with massive peritoneal disseminations is
still unsatisfactory.
2–6 Hence, there is a great deal of
interest in developing novel therapeutic agents, hopefully
as chemosensitizers.
As such candidates, a variety of gene therapies have
been tested by many laboratories researching on ovarian
cancer. These studies have used specific transgenes, most
of which induce apoptosis or cell cycle arrest, introduced
into tumors through plasmid or viral vector systems using
tumor-specific promoters.
7–9 Despite these efforts, the
levels of transgene expression have been insufficient to
eradicate tumors, mainly because of the unfavorable
characteristics of adenoviral vectors, in which the E1 gene
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CGT C CGTO Op pen enis deleted to inhibit the replicative capacity of the vector.
These non-replicative vectors have limited distribution
within the tumor mass after injection and are therefore
not suitable for advanced ovarian cancers, as this tumor
type frequently has multiple disseminated lesions
throughout the whole peritoneal cavity. To increase viral
spread to neighboring tumor cells or even distant lesions,
the use of replication-competent adenoviruses has become
a reality.
Many efforts have been made to realize cancer-specific
adenoviral replication using a variety of gene promoters,
including the prostate-specific antigen, MUC1, osteocal-
cin, L-plastin, midkine and E2F-1 genes.
10–15 Unfortu-
nately, these promoters have tissue-type specificity and
exhibit transcriptional activity only in cells that express
such tumor markers. Furthermore, the transcriptional
activity is relatively low. We were prompted by these
studies to use the human telomerase reverse transcriptase
(hTERT) promoter and established an oncolytic adeno-
virus vector (Telomelysin, OBP-301), which contains the
hTERT gene promoter upstream of the E1 gene in
adenovirus type 5 genome.
16 As hTERT expression is
highly specific to cancer cells
17–19 and the hTERT
promoter has stringent cancer specificity,
20 OBP-301 can
express E1 genes preferentially in cancer cells and thereby
replicate there with much higher efficiency than in normal
cells.
16
This virus system does not require any specific
transgenes to deliver, because vigorous viral replication
itself induces cell death as a result of viral toxicity. In
previous studies, in vivo direct injection of OBP-301 into
primary tumor sites led to efficient eradication of the
tumor without significant adverse effects in various
organs.
16,21,22 Considering the superior infectivity of
OBP-301 to not only primary tumors but also to the
surrounding and even distant tumors, we sought to apply
this virus to the treatment of ovarian cancers with
multiple disseminations. As a major therapeutic protocol
for ovarian cancer includes platinum-based chemother-
apy, we have a special interest in whether OBP-301 has
potential for additive or synergistic effects with cisplatin
(CDDP). Here, using an in vitro and in vivo mouse model
with peritoneal dissemination, we show the therapeutic
efficacy of intraperitoneal administration of OBP-301
combined with cisplatin on ovarian cancer.
Materials and methods
Cell culture
The human ovarian cancer cell line, SKOV3, and normal
primary human fibroblasts (Takara, Tokyo, Japan) were
cultured at 371C under 5% CO2 in Dulbecco’s modified
Eagle’s medium, supplemented with 10% heat-inactivated
fetal calf serum (Sigma-Aldrich, St Louis, MO),
100mgml
–1 streptomycin and 100IUml
–1 penicillin.
KF28 cells were derived from serous cystadenocarcinoma
of the ovary, from which CDDP-resistant KFr13 cells
were established.
23 Both cells were cultured in the above
conditions.
Reagents and viruses
Cisplatin was provided by Bristol Pharmaceuticals KK
(Tokyo, Japan). OBP-301 (Telomelysin) is a telomerase-
specific replication-competent adenovirus, in which the
hTERT gene promoter has been inserted upstream of the
E1 gene in adenovirus type 5 genome.
16 A replication-
deficient variant of adenovirus type 5 (dl312) was used as
the control for oncolytic activity.
16 To visualize viruses
infected in vitro and in vivo, the green fluorescent protein
(GFP) gene was inserted into the OBP-301 genome (OBP-
401) under control of the cytomegalovirus (CMV)
promoter, so that OBP-401 expresses GFP in infected
cells and this expression can be detected by fluorescence
imaging.
24,25 The construction and features of these
viruses have been described in detail in our previous
studies.
16,24,26,27 The viruses were purified by CsCl2 linear
gradient ultracentrifugation. The viral titers were deter-
mined by a plaque-forming assay using 293 cells.
Cell viability assay
The cytotoxicity of the viruses and/or CDDP was
evaluated using WST-1 reagent (Roche Diagnostics,
Tokyo, Japan). Briefly, 1 10
3 cells were seeded in 96-
well plates 24h before treatment. Cells were treated with
virus alone at the indicated multiplicity of infections
(MOIs) and concentrations, respectively, for 24, 48, 72
and 96h. In combination assay, cells were infected with
virus at various MOIs and exposed to CDDP at various
concentrations for 48h. Then, a total of 10ml of WST-1
reagent was added to each well, and the cells were further
incubated for 2h at 371C. Absorbance was measured
using a microscope reader at test and reference wave-
lengths of 450 and 655nm, respectively, to evaluate the
relative viability of the cells treated.
Animal experiments
Female 7–9-week-old BALB/c nu/nu mice (SLC,
Hamamatsu, Japan) were housed under specific patho-
gen-free conditions. Experiments proceeded according to
the institutional guidelines. To confirm that we could
produce a mouse model with peritoneal dissemination,
SKOV3 cells (1 10
7 cells) were injected into the
peritoneal space of the mice in 500ml phosphate-buffered
saline (PBS) and successful formation of disseminated
cancer foci in the peritoneal cavity was apparent B2–3
weeks after injection. We then decided to test four groups
of mice as follows: OBP-301 alone, CDDP alone,
CDDPþOBP-301 and PBS only (the mock group).
Disease-free BALB/c nu/nu mice were inoculated with
1 10 SKOV3 cells (day 0) and then 0.5mgkg
–1 CDDP in
a total volume of 1ml was injected into the peritoneal
space once per day on days 1, 3 and 5. Then 10
8pfu of
OBP-301 was injected into the peritoneal space once per
day on days 7, 9 and 11, followed by weekly injections of
10
8pfu of OBP-301 until the killing. In the OBP-301 alone
and CDDP alone groups, PBS was injected instead of
CDDP or OBP-301, respectively. In the mock group only
PBS was injected. Six mice in each group were treated
according to this protocol and were killed 50 days after
inoculation of SKOV3 cells to observe the peritoneal
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counting the number of peritoneal disseminations and
evaluating the overall survival (OS).
In vitro and In vivo fluorescence imaging
SKOV3 and normal human fibroblasts were infected with
OBP-401 at an MOI of 10 and GFP expression was
assessed and photographed ( 200) by an Eclipse TS-100
fluorescent microscope (Nikon, Tokyo, Japan) 24h after
infection. In vivo GFP fluorescence imaging was acquired
by illuminating the animal with a Xenon 150-W lamp
after an intraperitoneal injection of 10
8pfu of OBP-401.
The re-emitted fluorescence was collected through a long
pass filter on a Hamamatsu C5810 three-chip color cooled
charged-coupled device (CCD) camera (Hamamatsu
Photonics Systems, Hamamatsu, Japan). High-resolution
image acquisition was accomplished using an EPSON
(Tokyo, Japan) personal computer. Images were pro-
cessed for contrast and brightness with the use of Adobe
Photoshop 4.0.1J software.
Statistical analysis
To assess the statistical significance of differences of the
number of disseminated lesions, a standard two-tailed
Student’s t-test was performed using Microsoft Excel
2004. Life tables were computed using the Kaplan–Meier
method, and the Log-rank test was used to assess
statistical significance. A P-value of o0.05 was consid-
ered to indicate statistical significance.
Results
In vitro effect of OBP-301 on human ovarian cancer cell
line and normal cells
To examine the in vitro effect of OBP-301 on an ovarian
cancer cell line, we infected the human ovarian cancer cell
line SKOV3 and normal human fibroblast with OBP-301
and a replication-deficient variant (dl312) at various
MOIs. Cell viability was assessed by the WST-1 assay
4 days after infection. Approximately 30–70% of SKOV3
cells were killed by OBP-301 at MOIs of 10–100,
respectively (Figure 1a), whereas dl312 failed to kill any
cells even at an MOI of 100 (Figure 1b), showing that the
replicative capacity of the virus is crucial for the cytotoxic
effect on ovarian cancer cells. In contrast, no cytotoxic
effects were observed in normal fibroblasts 4 days after
infection of OBP-301, even at an MOI of 100 (Figure 1c),
clearly indicating the cancer-specific cytotoxicity of
OBP-301. Next, we examined the combinatorial effect of
OBP-301 with CDDP, which is a key drug for advanced
ovarian cancer. OBP-301 was infected into SKOV3 cells
at various concentrations, with or without 0–4mM CDDP.
Cell variability was measured 72h after infection. In the
absence of CDDP, B40% of SKOV3 cells were killed by
OBP-301 at an MOI of 100, whereas 20% were killed at
an MOI of 1–10 (Figure 2). The treatment of SKOV3 with
0–4mM CDDP alone (mock) induced about 20% cell
death at 0.5–1mM and 40% death at 2mM. When CDDP
at 0.5–1mM was combined with OBP-301 (1–100 MOI),
the ratio of killed cells increased by 20%, resulting in a
total of 40% cell death. When CDDP at 2mM was
combined with OBP-301 (100 MOI), the ratio of killed
0.01 MOI
0.1   MOI
SKOV3-OBP-301
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Figure 1 In vitro cytotoxic effects of OBP-301 on cancer and
normal cells. Human ovarian cancer cell line, SKOV3 cells (a), and
normal human fibroblasts (c) were infected with OBP-301 at various
multiplicity of infections (MOIs), and the cell viability was assessed
daily by WST-1 assay until 4 days after infection. SKOV3 cells were
also infected with replication-deficient adenoviral vectors (dl312)
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Figure 2 Combinatorial effects of OBP-301 and cisplatin on
SKOV3 cells. SKOV3 cells were infected with OBP-301 at various
multiplicity of infections (MOIs) and exposed to cisplatin at the
indicated concentrations for 72h. Then, the cell viability was
measured by WST-1 assay. Bars indicate s.e.
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cell death. The treatment with CDDP alone at 4mM
resulted in B70% cell death, and the additive effects of
OBP-301 were limited, with o10% increase in cell death
even at 100 MOI. These findings suggest that OBP-301
has potent cytotoxic activity against ovarian cancer cells
in vitro at an MOI of 1–100, and significantly enhances
the effects of low-dose CDDP, which otherwise showed
lesser cytotoxicity.
We further examined whether OBP-301 has cytotoxic
activity or sensitizing effect on CDDP-resistant ovarian
cancer cells as well. For this purpose, we used CDDP-
resistant ovarian cancer cell line, KFr13 cells, established
from KF28 cells derived from human serous cystadeno-
carcinoma of the ovary.
23 The IC50 of CDDP was
compared among KF28, KFr13 and SKOV3 cells and is
shown in Figure 3a. KFr13 cells exhibited much higher
IC50 than KF28 or SKOV3 cells, as expected. We then
treated KFr13 cells with CDDP at various concentrations
in the presence or absence of OBP-301 and examined the
combinatorial effect. As shown in Figure 3b, the
treatment of CDDP alone at 1–4mM induced no
significant death of this cell line. When CDDP at 1–4mM
was combined with OBP-301 at 1 MOI, the ratio of
killed cells increased up to 10–40%, according to the
concentration of CDDP. The treatment with CDDP alone
at 8mM resulted in B70% cell death, and the ratio of
killed cells increased by 20% by the combination.
Surprisingly, this cell line was very sensitive to OBP-301
because the treatment with OBP-301 alone at 10 MOI
resulted in 480% cell death, irrespectively of the CDDP
treatment. We also tested the effects of OBP-301 on
another CDDP-resistant ovarian cancer cell, CaOV3.
28
OBP-301 had similar cytotoxic effect on this cell line (data
not shown). These findings indicate that OBP-301 has
cytotoxic and sensitizing effect on CDDP-resistant
ovarian cancer cells.
Visualization of infected viruses using the GFP gene in
vitro and in vivo
To confirm the specific effects of OBP-301 on ovarian
cancer cells, we decided to confirm the localization of
infected viruses, hopefully by visualizing the viruses.
Thus, the GFP gene driven by the CMV promoter was
inserted into OBP-301 so that the viruses could express
GFP by efficient replication in infected cells (Figure 4a).
This chimeric virus was named OBP-401.
24,25 We first
infected OBP-401 into SKOV3 and normal human
fibroblast at an MOI of 10 in vitro. Apparent expression
of GFP was observed in SKOV3 cells (Figure 4b, right
panel); however, only faint GFP signals were detected in
normal human fibroblasts (Figure 4b, left panel), clearly
indicating the cancer-specific replication of OBP-401
in vitro. Next, to assess the localization of intraperitone-
ally injected virus, we established an in vivo mouse
model of ovarian cancer cells, in which 1 10
7 SKOV3
cells were inoculated into the peritoneal cavity of nude
mice, leading to the formation of peritoneal dissemina-
tions. OBP-401 was then injected into the peritoneal
cavity 4 weeks after the initial inoculation with the cancer
cells. The mice were killed 72h after OBP-401 injection
and GFP expression was observed. GFP expression was
found to be localized mainly at the surface of dissemi-
nated cancer lesions (Figure 4c, left panel). We even
detected GFP expression in small lesions that were only
detectable with a microscope, not by macroscopic
observation (Figure 4c, right panel). These findings
suggest that our viruses injected into the peritoneal
cavity exhibit preferential and specific distribution in
disseminated cancer foci.
In vivo effect of intraperitoneal administration of
OBP-301 in combination with CDDP on peritoneal
dissemination of ovarian cancer cells
As the use of platinum-based chemotherapeutic agents
has commonly been accepted as the standard therapy
for advanced ovarian cancer, we examined the in vivo
effects of OBP-301 alone, CDDP alone or OBP-301
combined with CDDP using a mouse model with
peritoneal dissemination (Figure 5a, see Materials
and methods). The numbers of peritoneal disseminated
lesions were then counted in each treatment group
(Figure 5b). Administration of CDDP alone did not
significantly reduce the number of disseminated lesions
compared with the mock-treated mice, whereas treatment
with OBP-301 alone led to a significant reduction
in disseminated lesions (Po0.05). The combination of
































































Figure 3 Combinatorial effects of OBP-301 and cisplatin on CDDP-
resistant KFr13 cells. (a) CDDP-sensitive KF28 and SKOV3 cells
and CDDP-resistant KFr13 cells were treated with CDDP at various
concentrations for 5 days. Then, the cell viability was measured by
WST-1 assay, and IC50 of CDDP was calculated in each cell line.
Bars indicate s.e. (b) CDDP-resistant KFr13 cells were infected with
OBP-301 at various multiplicity of infections (MOIs) and exposed to
cisplatin at the indicated concentrations for 72h. Then, the cell
viability was measured by WST-1 assay. Bars indicate s.e.
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or OBP-301 alone (Po0.001, Po0.01, respectively).
A representative picture of the peritoneal cavities of
two mice is shown in Figure 4c. Massive progression
of the peritoneal disseminations can be seen in the
mock-treated mouse, whereas markedly fewer and smaller
disseminated tumors are evident in the CDDP/ OBP-
301-treated mouse.
To clarify the survival effect of intraperitoneal admin-
istration of OBP-301, three groups of mice treated with
PBS alone (mock), CDDP alone or CDDP combined with
OBP-301 were further monitored for mortality until 120
days after inoculation of cancer cells (Figure 6). All mock-
treated mice died around days 50–60, whereas CDDP
alone extended survival, with a 50% OS rate at day
60 and 17% at day 120. Co-treatment with OBP-301
further extended survival, achieving 100% OS at day
80 and 83% at day 120. Thus, the prognosis was
significantly improved by the combination of CDDP with
OBP-301. Taken together, these findings suggest that
intraperitoneal administration of OBP-301 sensitizes
ovarian cancer cells to CDDP and may be a useful
treatment option for advanced ovarian cancer with
peritoneal dissemination.
Discussion
In this study, we showed the therapeutic potential of
intraperitoneal administration of OBP-301 in combina-
tion with CDDP for advanced ovarian cancers with
peritoneal dissemination. A series of our previous studies
have shown the anti-tumor effects of OBP-301 in various
types of cancers, including lung and colorectal cancers
both in vitro and in vivo,
16,21,22,24–27 and a clinical trial of
OBP-301 therapy as monotherapy is currently underway
based on these preclinical studies.
29 However, these
preclinical and clinical studies have been carried out
mainly by direct injection of OBP-301 into primary tumor
sites. This study is the first to test the effect of
intraperitoneal administration of OBP-301.
Our in vitro data showed that OBP-301 alone has
marked anti-tumor effects on SKOV3 cells at an MOI of
100, whereas modest to mild effects were observed at an
MOI of 10 or lower (Figure 1). However, such low-dose
OBP-301 did have a sensitizing effect on SKOV3 cells to
CDDP in vitro (Figure 2), rendering the cytotoxicity of
low-dose CDDP (0.5mM) equivalent to that of high-dose
CDDP (2mM). We also confirmed that similar sensitizing
effect was observed in CDDP-resistant cells (Figure 3).
E1A
hTERT promoter CMV promoter
E1B GFP
SKOV3 Normal human fibroblast
Figure 4 Visualization of infected OBP adenoviruses by green fluorescent protein (GFP) expression. To visualize OBP-301 in vitro and in vivo,
the GFP gene driven by the cytomegalovirus (CMV) promoter was inserted into the genome of OBP-301, named OBP-401 (a). SKOV3 and
normal human fibroblasts were infected with OBP-401 at an multiplicity of infection (MOI) of 10 and GFP expression was assessed using a
fluorescence microscope (b). SKOV3 cells (1 10
7 cells) were inoculated into the peritoneal cavity of BALB/c nu/nu mice and OBP-401 was
injected into the peritoneal cavity 4 weeks later. The mice were killed and GFP expression was assessed 72h after injection of OBP-401 (c).
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seemed to have higher sensitivity to OBP-301 than
CDDP-sensitive SKOV3 cells. These finding suggest the
therapeutic potential of OBP-301, irrespectively of the
CDDP sensitivity of target cells. The beneficial combined
effect of OBP-301 with CDDP was further supported by
the in vivo analysis. Although the number of disseminated
lesions was not significantly altered by low-dose CDDP
(0.5mgkg
–1) alone, the number significantly decreased by
the addition of OBP-301 to CDDP (Po0.01) (Figure 5).
The molecular mechanism through which OBP-301
sensitizes cells to CDDP was not analyzed in this study,
but it is likely that OBP-301 and CDDP produce their
cytotoxic activities through different mechanisms. We
also confirmed that the replicative efficacy of OBP-301
was not affected by CDDP treatment in vitro and that
OBP-301 infection had no effect on cell cycle distribution
(data not shown). Therefore, the anti-tumor mechanisms
of the two agents seem to be independent of each other.
We also confirmed that the nuclear morphology of cells
infected with OBP-301 did not exhibit findings of
apoptosis characterized by chromosome condensation,
nuclear shrinkage and fragmentation (data not shown).
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Figure 5 In vivo effect of intraperitoneal administration of CDDP and/or OB-301 on peritoneal disseminations of SKOV3. (a) Protocol of
intraperitoneal administration of CDDP and/or OB-301. After the inoculation of 1 10
7 SKOV3 cells (day 0), 0.5mgkg
–1 CDDP was injected into
the peritoneal cavity once a day on days 1, 3 and 5. Then, 10
8pfu of OBP-301 was injected into the peritoneal cavity once a day on days 7, 9 and
11 followed by weekly injection of 10
8pfu of OBP-301 until the killing. Arrows indicate the day of treatment. (b) The numbers of peritoneal
disseminated lesions were counted in each treatment group 50 days after inoculation of SKOV3 cells. Bars, s.d. (c) Representative picture of the
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Figure 6 Survival of mice treated with intraperitoneal administration
of CDDP and/ or OB-301. Kaplan–Meier plots of overall survival of
the no treatment, CDDP alone and CDDPþOBP-301 groups. Each
group consisted of six mice. *Po0.05.
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infection with OBP-301 (data not shown). The in vitro
dose-response curves of CDDP combined with OBP-301
show that the interaction between the two agents is
additive, not synergistic, suggesting that OBP-301 targets
cells that have escaped death by CDDP, leading to an
additive effect. Interestingly, intraperitoneal administra-
tion of OBP-301 in combination with CDDP induced a
more pronounced growth inhibitory effect, that is, a
synergistic effect, in vivo than in vitro (Figure 5), suggest-
ing particular interactions between OBP-301 and CDDP
in vivo. Similar synergistic effects of OBP-301 in vivo, but
not in vitro, have been reported with other cytotoxic
agents.
21 One possible explanation for the augmented
cytotoxicity observed in vivo might be that the blood
supply to tumor lesions is disturbed by the actions of
OBP-301, in which intraperitoneal administration of
OBP-301 may attack endothelial cells of microvessels in
disseminated lesions and thereby enhance the cytotoxic
effects of CDDP. Although microvessels are mouse
origin, hTERT promoter might function in such cells
because it has very similar context of the sequences with
the mouse TERT promoter
30 and it can be activated in
proliferation-competent normal cells, such as endothelial
cells in tumor microvessels.
31–33 Alternatively, CDDP
treatment affects the immunological circumstances of the
host, disturbing the functions of macrophages and other
immune cells, which may provide some advantage to
OBP-301 in its infectivity and replicative capacity in
cancer tissues. Finally, we tested the change in expression
of various genes involved in drug resistance, such as
MDR1, MRP1, LRP and GST, 24h after the treatment
with OBP-301 at 100 MOI. However, reverse transcrip-
tase–PCR assays failed to find any specific factors whose
expression was significantly regulated by the treatment
(data not shown). Further analyses are needed to identify
the molecular mechanisms of the synergistic effects by
both agents in vivo.
Although this study did not investigate the adverse
effects on mice, our previous studies showed no sig-
nificant toxicity of OBP-301 on normal human
cells.
16,21,22,24,25 This is likely because of the use of the
hTERT promoter for tumor-specific expression of the E1
gene. Although the hTERT promoter is reported to be
silent in normal cells, it may provide some transcriptional
activity in some cell types with telomerase activity, such as
stem or germ-line cells.
31–33 It is therefore possible that
these telomerase-positive normal cells might be targeted
by OBP-301. Nevertheless, severe adverse effects due to
OBP-301 have not been reported. One possible explana-
tion of this favorable phenomenon is that cells with stem-
like characteristics are usually non-epithelial in origin and
are therefore not likely to be targeted by adenoviral
vectors.
34 Alternatively, the levels of telomerase activity in
cells with stem-like characteristics are not as high as in
cancer cells unless the cells are exposed to ectopic
mitogenic stimuli.
32,33 Therefore, the cytotoxicity by
OBP-301 might be limited or permissive in such cells.
Platinum-based chemotherapy has widely been ac-
cepted as the standard regimen for both neoadjuvant
and adjuvant settings for advanced ovarian cancer.
1
However, B30–40% of patients have resistance to
platinum-based chemotherapy, and even sensitive patients
frequently acquire resistance after repeated cycles of
CDDP-based chemotherapy.
2–6 In this study, we found
that OBP-301 was useful for CDDP-resistant ovarian
cancer cells, indicating the therapeutic potential of this
agent, irrespectively of the CDDP sensitivity of target
cells. Furthermore, we found that use of OBP-301 alone
had cytotoxic effects in vitro at an MOI of 100, but
exhibited more pronounced effects in vivo at an MOI of
10, decreasing the number of disseminations (Figure 5).
Although we did not examine the survival effect of OBP-
301 alone, patients who relapse with acquired CDDP
resistance may be able to use OBP-301 alone.
The most notable finding of this study is that addition
of intraperitoneal injection of OBP-301 improved the
survival of mice. Our treatment modality is characterized
by continuous weekly administration of OBP-301 after
CDDP treatment. As one of the major purposes of this
strategy is to reduce the total dose of CDDP delivered,
thereby reducing its adverse effects, we did not test weekly
combined administration of OBP-301 and CDDP. Our
data indicate that continuous weekly OBP-301 adminis-
tration after CDDP treatment has some survival effect
and is a practical regimen for minimizing the adverse
effects of CDDP.
We are currently investigating the combinatorial
actions of OBP-301 with taxans, other key drugs for
ovarian cancers. In fact, the combination therapy of
taxans and CDDP/carboplatin is now a novel standard of
chemotherapy for ovarian cancer. Therefore, it is
necessary to investigate the best modality by which to
combine OBP-301 with such standard regimens. Further-
more, it is of great interest to test the possibility of
combination therapy of OBP-301 with the recently
established molecular target therapies, such as signal
transduction inhibitors, to provide relief to patients with
ovarian cancers who have acquired resistance to standard
therapy.
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